Derivation Web

source_d427bb9d5f2c4973

by researka:v2 · 2026-07-27 06:50:47.113304+04:00

# Research Synthesis: Metformin Treatment Effects — full paper

## Abstract

Evidence scope: 18/33 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims (evidence anchor: Park 2024 [bundle:2]) [exact source: https://doi.org/10.4093/dmj.2023.0259].

Metformin remains the first-line glucose-lowering agent for type 2 diabetes, and the breadth of its purported cardiometabolic, anti-inflammatory, frailty-prevention, and longevity effects has motivated an expanding human evidence base that this synthesis attempts to consolidate (ADA 2024).

We conducted an AI-assisted structured evidence synthesis in which each candidate record was scored for design, directness, and outcome class, with a full audit trail retained so that direct randomized evidence could be kept analytically separate from indirect or mechanistic/biomarker findings.

Across the corpus, direct randomized evidence supports metformin's role as an effective glucose-lowering backbone in type 2 diabetes with some ancillary cardiometabolic gains, but does not yet support its repurposing for frailty prevention, longevity, or hard anti-inflammatory outcomes, and several body-composition effects conflict across populations (evidence anchor: Park 2024 [bundle:2]) [exact source: https://doi.org/10.4093/dmj.2023.0259].

The boundary conditions — baseline glycemic status, age, exercise co-intervention, and background therapy — remain inadequately characterized, and the mechanistic/biomarker literature should be interpreted as hypothesis-generating rather than as confirmation of clinical benefit until adequately powered direct trials in non-diabetic older or at-risk populations report (evidence anchor: Park 2024 [bundle:2]) [exact source: https://doi.org/10.4093/dmj.2023.0259].

## Research Question

Within the retained source corpus for metformin treatment effects, among adults, do findings for cardiometabolic and contextual adjacent evidence support a decision-grade conclusion (clinically actionable where applicable), and which population, study-design, and directness boundaries keep extrapolation to other outcome classes hypothesis-generating?

## Introduction

This synthesis evaluates evidence on metformin treatment effects across 33 included source papers and 2183 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

No retained source is classified primarily as mechanistic or model-system evidence under the source-level directness schema; however, mechanistic or biomarker content can occur within sources classified by their primary study role, so this is a classification statement and not evidence that mechanistic content is absent. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

## Background

The background evidence for metformin treatment effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Schiapaccassa 2019 [bundle:33], Park 2024 [bundle:2], Qin 2025 [bundle:3] are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation [exact source: https://doi.org/10.4093/dmj.2023.0259].

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect (evidence anchor: Abed 2024 [bundle:18]) [exact source: https://doi.org/10.1186/s13018-024-05120-0].

Across the retained sources, positive signals cluster around the cardiometabolic outcome class; null signals around the contextual adjacent evidence, frailty and cardiometabolic outcome classes; and negative or adverse signals around the cardiometabolic, immune and inflammation outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation (evidence anchor: Park 2024 [bundle:2]) [exact source: https://doi.org/10.4093/dmj.2023.0259].

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-metformin_intervention_metformin_treatment_effects-v06-DAILY-2026-07-27T02-47-31Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-27.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `metformin intervention metformin treatment effects aging`
- `metformin intervention metformin treatment effects older adults`
- `metformin intervention metformin treatment effects randomized controlled trial`
- `metformin aging`
- `metformin older adults`
- `metformin randomized controlled trial`
- `intervention metformin treatment aging`
- `intervention metformin treatment older adults`
- `intervention metformin treatment randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses metformin intervention metformin treatment effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
Of 33 records retrieved, 33 were screened against the eligibility criteria, 33 were included in the synthesis, and 0 were excluded at full-text review. Reasons for exclusion are summarised below.

### Exclusion reasons
- No additional records were excluded after final source admission; upstream non-admission buckets are reported separately in the receipt funnel and are not post-admission exclusions.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, frailty, immune and inflammation, longevity, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates (evidence anchor: Park 2024 [bundle:2]) [exact source: https://doi.org/10.4093/dmj.2023.0259].

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

Mechanistic-content clarification: No retained source is classified primarily as mechanistic or model-system evidence under the source-level schema. Mechanistic or biomarker content can still occur within those sources, so this is not evidence that mechanistic content is absent.

Publication-status/preprint note: 2026-dated manifest sources are Guo 2026 [bundle:1], Sahay 2026 [bundle:4], Mohan 2026 [bundle:5], Malin 2026a [bundle:6], Malin 2026b [bundle:11], Marcelo-Calvo 2026 [bundle:12], Iraji 2026 [bundle:13], Kumari 2026 [bundle:15]; preprint candidates flagged by manifest metadata: none [exact source: https://doi.org/10.1111/dom.70778].

Source directness breakdown: 15/33 retained sources directly address the stated topic and aging-relevant hard endpoints; 18/33 are adjacent, contextual, review-level, or mechanistic and are used only to bound interpretation. A qualifying direct source would directly test the named exposure or construct in the target population with aging-relevant clinical or hard-endpoint follow-up. Inclusion rationale: adjacent sources are reclassified as contextual rather than used for broad efficacy claims. Reviewer-classification audit: when feedback names a source as misclassified or off-topic, the public map below uses source-title subdomain labels to separate prognostic, causal-risk, mechanistic, intervention-response, and adjacent-context roles rather than relying only on stale manifest outcome labels (evidence anchor: Mueller 2021 [bundle:8]) [exact source: https://doi.org/10.2337/dc20-2257].

### Source Classification Map

- Schiapaccassa 2019 [bundle:33]: outcome=Immune and Inflammation; direction=mixed; directness=direct; tier=A1.
- Guo 2026 [bundle:1]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2.
- Park 2024 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1.
- Qin 2025 [bundle:3]: outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1.
- Sahay 2026 [bundle:4]: outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1.
- Mohan 2026 [bundle:5]: outcome=Cardiometabolic; direction=negative; directness=direct; tier=A1.
- Malin 2026a [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=indirect; tier=B2.
- Han 2020 [bundle:7]: outcome=Cardiometabolic; direction=positive; directness=direct; tier=A1.

Substantive evidence synthesis: The included evidence set comprises 33 retained sources, 15 direct sources, and source-level directional coding across mixed=2, negative=4, null=5, positive=3, unclear=19. Source-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Representative source-level signals are: Schiapaccassa 2019 [bundle:33]: outcome=Immune and Inflammation; direction=mixed; directness=direct; tier=A1; result=30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal; finding=229 extracted claim(s); receipt-level direction is the coded finding; claims=229; Guo 2026 [bundle:1]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin; finding=170 extracted claim(s); receipt-level direction is the coded finding; claims=170; Park 2024 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1; result=Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with; finding=161 extracted claim(s); receipt-level direction is the coded finding; claims=161; Qin 2025 [bundle:3]: outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1; result=Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with; finding=149 extracted claim(s); receipt-level direction is the coded finding; claims=149; Sahay 2026 [bundle:4]: outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1; result=Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose; finding=144 extracted claim(s); receipt-level direction is the coded finding; claims=144; Mohan 2026 [bundle:5]: outcome=Cardiometabolic; direction=negative; directness=direct; tier=A1; result=Efficacy and Safety of Glimepiride, Voglibose, and Metformin ER in Type 2 Diabetes: A Randomized, Active‐Controlled; finding=132 extracted claim(s); receipt-level direction is the coded finding; claims=132; Malin 2026a [bundle:6]: outcome=Cardiometabolic; direction=positive; directness=indirect; tier=B2; result=Metformin attenuates metabolic insulin sensitivity and insulin‐stimulated carbohydrate oxidation after high‐intensity; finding=representative statistic p = 0.017; source-level statistic reported; claims=124; Han 2020 [bundle:7]: outcome=Cardiometabolic; direction=positive; directness=direct; tier=A1; result=Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with; finding=representative statistic p = 0.002; source-level statistic reported; claims=108 [exact source: https://doi.org/10.4093/dmj.2023.0259]. These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating.

### Findings Map

Findings Map completeness note: all 33 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

Findings Map accounting note: each outcome-class n, direction count, directness count, and source roster is computed from the same source-level rows listed in the detailed table. Receipt-level direction is not a statement that the source abstracts lack directional statistics; it is the conservative coded polarity used for synthesis accounting. Outcome-class roster: Cardiometabolic n=19 (direction: mixed=1; negative=3; null=1; positive=3; unclear=11; directness: direct=9; indirect=10; sources: Agarwal 2026 [bundle:16]; Behbudi 2025 [bundle:21]; Comparison of Efficacy and Safety 2022 [bundle:32]; Espinoza 2025a [bundle:28]; Guo 2021 [bundle:14]; Guo 2026 [bundle:1]; Han 2020 [bundle:7]; Hu 2021 [bundle:9]; Inzucchi 2020 [bundle:22]; Kim 2024 [bundle:10]; Kumari 2026 [bundle:15]; Malin 2026a [bundle:6]; Malin 2026b [bundle:11]; Mohan 2026 [bundle:5]; Park 2024 [bundle:2]; Qin 2025 [bundle:3]; Sahay 2026 [bundle:4]; Shadyab 2025 [bundle:20]; Shen 2026 [bundle:23]); Contextual Adjacent Evidence n=7 (direction: null=2; unclear=5; directness: direct=2; indirect=5; sources: Bilusic 2026 [bundle:25]; Espinoza 2025b [bundle:29]; Iraji 2026 [bundle:13]; Li 2025 [bundle:17]; Marcelo-Calvo 2026 [bundle:12]; Mueller 2021 [bundle:8]; R 2026 [bundle:24]); Frailty n=2 (direction: null=2; directness: direct=1; indirect=1; sources: Espinoza 2022 [bundle:27]; Tavabi 2021 [bundle:26]); Immune and Inflammation n=2 (direction: mixed=1; negative=1; directness: direct=2; sources: Effects of Metformin on Biomarkers 2026 [bundle:31]; Schiapaccassa 2019 [bundle:33]); Longevity n=2 (direction: unclear=2; directness: indirect=2; sources: Maio 2026 [bundle:19]; Orchard 2021 [bundle:30]); Safety and Comorbidity n=1 (direction: unclear=1; directness: direct=1; sources: Abed 2024 [bundle:18]) [exact source: https://doi.org/10.4093/dmj.2023.0259].

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Agarwal 2026: Dapagliflozin Plus Metformin Versus Metformin Alone in Overweight and Obese Patients with Polycystic Ovary Syndrome - An Open-Label, Parallel, Randomized Controlled Trial | direction=negative | directness=direct | A1 | outcome=Cardiometabolic; direction=negative | finding=51 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Behbudi 2025: Effect of Metformin on Clinical Course of Non-Diabetic Patients with Ischemic Stroke | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P=0.021; source-level statistic reported |
| Cardiometabolic | Comparison of Efficacy and Safety 2022: Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=representative statistic P < 0.05; source-level statistic reported |
| Cardiometabolic | Espinoza 2025a: A 2-year Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=11 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Guo 2021: Comparison of Clinical Efficacy and Safety of Metformin Sustained-Release Tablet (II) (Dulening) and Metformin Tablet (Glucophage) in Treatment of Type 2 Diabetes Mellitus | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative non-significant statistic p>0.05; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Guo 2026: HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=170 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Han 2020: Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial | direction=positive | directness=direct | A1 | outcome=Cardiometabolic; direction=positive | finding=representative statistic p = 0.002; source-level statistic reported |
| Cardiometabolic | Hu 2021: Effects of a Behavioral Weight Loss Intervention and Metformin Treatment on Serum Urate: Results from a Randomized Clinical Trial | direction=positive | directness=direct | A1 | outcome=Cardiometabolic; direction=positive | finding=73 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Inzucchi 2020: MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic p<0.0001; source-level statistic reported |
| Cardiometabolic | Kim 2024: A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study) | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=70 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Kumari 2026: Comparative Study of the Efficacy of Ranolazine as Add-On Therapy With Metformin Versus Metformin Monotherapy on Glycaemic Control in Patients of Type 2 Diabetes Mellitus | direction=negative | directness=indirect | B2 | outcome=Cardiometabolic; direction=negative | finding=representative statistic p=0.022; source-level statistic reported |
| Cardiometabolic | Malin 2026a: Metformin attenuates metabolic insulin sensitivity and insulin‐stimulated carbohydrate oxidation after high‐intensity exercise training in adults at risk for metabolic syndrome | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic p = 0.017; source-level statistic reported |
| Cardiometabolic | Malin 2026b: Metformin Alters Exercise Training Induced Blood Pressure and Aortic Waveform Adaptations in Adults at Risk for Metabolic Syndrome | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative non-significant statistic p = 0.051; not treated as positive or negative directional support unless source direction is coded |
| Cardiometabolic | Mohan 2026: Efficacy and Safety of Glimepiride, Voglibose, and Metformin ER in Type 2 Diabetes: A Randomized, Active‐Controlled Study | direction=negative | directness=direct | A1 | outcome=Cardiometabolic; direction=negative | finding=132 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Park 2024: Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=161 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Qin 2025: Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with type 2 diabetes: A single-center, prospective, randomized, controlled, noninferiority study with genetic polymorphism analysis | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=149 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Sahay 2026: Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study | direction=unclear | directness=direct | A1 | outcome=Cardiometabolic; direction=unclear | finding=144 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Shadyab 2025: Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=34 extracted claim(s); receipt-level direction is the coded finding |
| Cardiometabolic | Shen 2026: Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug‐Target Mendelian Randomization Study | direction=mixed | directness=indirect | B2 | outcome=Cardiometabolic; direction=mixed | finding=representative statistic p = 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Bilusic 2026: The anti-obesogenic metabolite, Lac-Phe, is elevated by metformin treatment in prostate cancer patients | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=17 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | Espinoza 2025b: METFORMIN TO TARGET FRAILTY IN OLDER ADULTS | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=11 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | Iraji 2026: Comparison of the Efficacy of Kligman's Formula Combined With 30% Topical Metformin Versus Kligman's Formula Alone in the Treatment of Melasma | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=65 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | Li 2025: Medication count, including statin or metformin use, is not associated with influenza vaccine responses in older adults | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=49 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | Marcelo-Calvo 2026: Metformin and epigenetic age in non-diabetic older people with HIV in Madrid (METFORAGING): a double-blind, randomised, placebo-controlled, pilot trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=65 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | Mueller 2021: Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=107 extracted claim(s); receipt-level direction is the coded finding |
| Contextual Adjacent Evidence | R 2026: Metformin Repurposing in Neurological Disorders: A Clinical Trial Landscape | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=20 extracted claim(s); receipt-level direction is the coded finding |
| Frailty | Espinoza 2022: CLINICAL TRIAL OF METFORMIN FOR FRAILTY PREVENTION IN COMMUNITY-DWELLING OLDER ADULTS WITH PRE-DIABETES | direction=null | directness=indirect | B2 | outcome=Frailty; direction=null | finding=13 extracted claim(s); receipt-level direction is the coded finding |
| Frailty | Tavabi 2021: A Randomized Placebo-Controlled Trial of Metformin for Frailty Prevention in Older Adults | direction=null | directness=direct | A1 | outcome=Frailty; direction=null | finding=15 extracted claim(s); receipt-level direction is the coded finding |
| Immune and Inflammation | Effects of Metformin on Biomarkers 2026: 3778 Effects of metformin on biomarkers in older people with sarcopenia: analysis from the MET-PREVENT randomised controlled trial | direction=negative | directness=direct | A1 | outcome=Immune and Inflammation; direction=negative | finding=2 extracted claim(s); receipt-level direction is the coded finding |
| Immune and Inflammation | Schiapaccassa 2019: 30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal peptides on drug-naïve women with diabetes and obesity: a randomized head-to-head metformin-controlled study | direction=mixed | directness=direct | A1 | outcome=Immune and Inflammation; direction=mixed | finding=229 extracted claim(s); receipt-level direction is the coded finding |
| Longevity | Maio 2026: Metformin exposure after glioblastoma diagnosis and mortality: A large population-based study | direction=unclear | directness=indirect | B2 | outcome=Longevity; direction=unclear | finding=41 extracted claim(s); receipt-level direction is the coded finding |
| Longevity | Orchard 2021: Associations between Metformin and Aspirin Use on Cancer Incidence and Mortality in Older Adults. | direction=unclear | directness=indirect | B2 | outcome=Longevity; direction=unclear | finding=8 extracted claim(s); receipt-level direction is the coded finding |
| Safety and Comorbidity | Abed 2024: Effects of metformin phonophoresis and exercise therapy on pain, range of motion, and physical function in chronic knee osteoarthritis: randomized clinical trial | direction=unclear | directness=direct | A1 | outcome=Safety and Comorbidity; direction=unclear | finding=representative nominally statistically significant statistic p > 0.05; not treated as positive or negative directional support unless source direction is coded |

## Key Findings

Key findings from source synthesis:

Outcome-class key findings:

- Han 2020 [bundle:7]: Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with; representative statistic p = 0.002; source-level statistic reported; outcome=Cardiometabolic; direction=positive; directness=direct; tier=A1 [exact source: https://doi.org/10.3390/jcm9010259].
- Abed 2024 [bundle:18]: Effects of metformin phonophoresis and exercise therapy on pain, range of motion, and physical function in chronic knee; representative non-significant statistic p > 0.05; not treated as positive or negative directional support unless source direction is coded; outcome=Safety and Comorbidity; direction=unclear; directness=direct; tier=A1 [exact source: https://doi.org/10.1186/s13018-024-05120-0].
- Comparison of Efficacy and Safety 2022 [bundle:32]: Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release; representative statistic P < 0.05; source-level statistic reported; outcome=Cardiometabolic; direction=null; directness=direct; tier=A1 [exact source: https://doi.org/10.5455/njppp.2022.12.062851202217862022].
- Malin 2026a [bundle:6]: Metformin attenuates metabolic insulin sensitivity and insulin‐stimulated carbohydrate oxidation after high‐intensity; representative statistic p = 0.017; source-level statistic reported; outcome=Cardiometabolic; direction=positive; directness=indirect; tier=B2 [exact source: https://doi.org/10.1111/dom.70478].
- Malin 2026b [bundle:11]: Metformin Alters Exercise Training Induced Blood Pressure and Aortic Waveform Adaptations in Adults at Risk for; representative non-significant statistic p = 0.051; not treated as positive or negative directional support unless source direction is coded; outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2 [exact source: https://doi.org/10.1111/jch.70215].

Source-level findings by outcome class:

- Cardiometabolic: Han 2020 [bundle:7] (Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with; representative statistic p = 0.002; source-level statistic reported; outcome=Cardiometabolic; direction=positive; directness=direct; tier=A1); Comparison of Efficacy and Safety 2022 [bundle:32] (Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release; representative statistic P < 0.05; source-level statistic reported; outcome=Cardiometabolic; direction=null; directness=direct; tier=A1); Malin 2026a [bundle:6] (Metformin attenuates metabolic insulin sensitivity and insulin‐stimulated carbohydrate oxidation after high‐intensity; representative statistic p = 0.017; source-level statistic reported; outcome=Cardiometabolic; direction=positive; directness=indirect; tier=B2) [exact source: https://doi.org/10.3390/jcm9010259].
- Contextual Adjacent Evidence: Mueller 2021 [bundle:8] (Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial; 107 extracted claim(s); receipt-level direction is the coded finding; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1); Marcelo-Calvo 2026 [bundle:12] (Metformin and epigenetic age in non-diabetic older people with HIV in Madrid (METFORAGING): a double-blind, randomised; 65 extracted claim(s); receipt-level direction is the coded finding; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1); Iraji 2026 [bundle:13] (Comparison of the Efficacy of Kligman's Formula Combined With 30% Topical Metformin Versus Kligman's Formula Alone in; 65 extracted claim(s); receipt-level direction is the coded finding; outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2) [exact source: https://doi.org/10.2337/dc20-2257].
- Frailty: Tavabi 2021 [bundle:26] (A Randomized Placebo-Controlled Trial of Metformin for Frailty Prevention in Older Adults; 15 extracted claim(s); receipt-level direction is the coded finding; outcome=Frailty; direction=null; directness=direct; tier=A1); Espinoza 2022 [bundle:27] (CLINICAL TRIAL OF METFORMIN FOR FRAILTY PREVENTION IN COMMUNITY-DWELLING OLDER ADULTS WITH PRE-DIABETES; 13 extracted claim(s); receipt-level direction is the coded finding; outcome=Frailty; direction=null; directness=indirect; tier=B2) [exact source: https://doi.org/10.1093/geroni/igab046.2991].
- Immune and Inflammation: Schiapaccassa 2019 [bundle:33] (30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal; 229 extracted claim(s); receipt-level direction is the coded finding; outcome=Immune and Inflammation; direction=mixed; directness=direct; tier=A1); Effects of Metformin on Biomarkers 2026 [bundle:31] (3778 Effects of metformin on biomarkers in older people with sarcopenia: analysis from the MET-PREVENT randomised; 2 extracted claim(s); receipt-level direction is the coded finding; outcome=Immune and Inflammation; direction=negative; directness=direct; tier=A1) [exact source: https://doi.org/10.1093/ageing/afaf368.097].
- Longevity: Maio 2026 [bundle:19] (Metformin exposure after glioblastoma diagnosis and mortality: A large population-based study; 41 extracted claim(s); receipt-level direction is the coded finding; outcome=Longevity; direction=unclear; directness=indirect; tier=B2); Orchard 2021 [bundle:30] (Associations between Metformin and Aspirin Use on Cancer Incidence and Mortality in Older Adults.; 8 extracted claim(s); receipt-level direction is the coded finding; outcome=Longevity; direction=unclear; directness=indirect; tier=B2) [exact source: https://doi.org/10.1093/noajnl/vdag041].
- Safety and Comorbidity: Abed 2024 [bundle:18] (Effects of metformin phonophoresis and exercise therapy on pain, range of motion, and physical function in chronic knee; representative non-significant statistic p > 0.05; not treated as positive or negative directional support unless source direction is coded; outcome=Safety and Comorbidity; direction=unclear; directness=direct; tier=A1) [exact source: https://doi.org/10.1186/s13018-024-05120-0].

Synthesis interpretation: These source-level findings connect risk-marker, mechanistic, and intervention-adjacent signals into follow-up hypotheses, not a clinical efficacy claim. Direct/interventional rows define the ceiling for applied interpretation; indirect prevalence, risk-association, mechanistic, protocol, and review rows define context and uncertainty. Representative coded source verdicts remain: Schiapaccassa 2019 [bundle:33]: outcome=Immune and Inflammation; direction=mixed; directness=direct; tier=A1; result=30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal; finding=229 extracted claim(s); receipt-level direction is the coded finding; claims=229; Guo 2026 [bundle:1]: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin; finding=170 extracted claim(s); receipt-level direction is the coded finding; claims=170; Park 2024 [bundle:2]: outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1; result=Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with; finding=161 extracted claim(s); receipt-level direction is the coded finding; claims=161; Qin 2025 [bundle:3]: outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1; result=Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with; finding=149 extracted claim(s); receipt-level direction is the coded finding; claims=149 [exact source: https://doi.org/10.4093/dmj.2023.0259]. The bounded conclusion follows from source direction, outcome class, evidence tier, and directness rather than from source count alone. Publication-year note: citation years follow the manifest metadata; when DOI/PubMed dates differ, the source should be treated as bibliographic/in-press metadata and not used for year-specific claims.

## Results

Source-direction reconciliation (Orchard 2021 [bundle:30]): reviewer-reconciled direction=mixed is used consistently; endpoint-specific findings remain separately qualified.

No extractable efficacy numerics are available for Frailty within the retained corpus; therefore no quantitative frailty claim is supported by the retained sources (evidence anchor: Tavabi 2021 [bundle:26]) [exact source: https://doi.org/10.1093/geroni/igab046.2991].

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim (evidence anchor: Mueller 2021 [bundle:8]) [exact source: https://doi.org/10.2337/dc20-2257].

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Metformin Intervention Metformin Treatment Effects / Cardiometabolic | n=19; claims=1495 | significant source statistic in 17/19 sources; receipt-level direction coded unclear | 9 direct; 10 indirect | limited corpus depth in this outcome class |
| Metformin Intervention Metformin Treatment Effects / Contextual Adjacent Evidence | n=7; claims=334 | significant source statistic in 5/7 sources; receipt-level direction coded unclear | 2 direct; 5 indirect | limited corpus depth in this outcome class |
| Metformin Intervention Metformin Treatment Effects / Frailty | n=2; claims=28 | no extracted directional signal in 2/2 sources | 1 direct; 1 indirect | limited corpus depth in this outcome class |
| Metformin Intervention Metformin Treatment Effects / Immune and Inflammation | n=2; claims=231 | negative signal in 1/2 sources | 2 direct | limited corpus depth in this outcome class |
| Metformin Intervention Metformin Treatment Effects / Longevity | n=2; claims=49 | unclear signal in 2/2 sources | 2 indirect | limited corpus depth in this outcome class |
| Metformin Intervention Metformin Treatment Effects / Safety and Comorbidity | n=1; claims=46 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 direct | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Aging and geroscience context: 7 sources; significant source statistic in 4/7 sources; receipt-level direction coded unclear.
- Oncology and cancer context: 3 sources; significant source statistic in 1/3 sources; receipt-level direction coded unclear.
- Dosing and pharmacokinetics context: 2 sources; significant source statistic in 1/2 sources; receipt-level direction coded unclear.
- Infectious-disease and immunology context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.

### Results Summary

- Cardiometabolic: n=19; claims=1495; mixed signal in 11/19 sources | directness: 9 direct; 10 indirect; main limitation: directionally heterogeneous.
- Contextual Adjacent Evidence: n=7; claims=334; mixed signal in 5/7 sources | directness: 2 direct; 5 indirect; main limitation: directionally heterogeneous.
- Frailty: n=2; claims=28; no extracted directional signal in 2/2 sources | directness: 1 direct; 1 indirect; main limitation: population and endpoint heterogeneity.
- Immune and Inflammation: n=2; claims=231; mixed signal in 1/2 sources | directness: 2 direct; main limitation: directionally heterogeneous.
- Longevity: n=2; claims=49; mixed signal in 2/2 sources | directness: 2 indirect; main limitation: no direct clinical anchor.
- Safety and Comorbidity: n=1; claims=46; mixed signal in 1/1 sources | directness: 1 direct; main limitation: single-source support.

### Cardiometabolic Outcomes

The cardiometabolic outcome class is the dominant analytical domain across the corpus, populated by 19 source entries spanning randomized clinical trials, observational cohorts, and Mendelian randomization designs.

Quantitative findings across the cardiometabolic class are heterogeneous. The Comparison of Efficacy and Safety 2022 [bundle:32] randomized open-label Phase IV trial of vildagliptin 50 mg twice daily versus vildagliptin 100 mg sustained-release once daily on top of metformin reported P < 0.05 [exact source: https://doi.org/10.5455/njppp.2022.12.062851202217862022].

Within-corpus tensions on cardiometabolic outcomes are concentrated around body mass index and body weight, where directness and directionality diverge. Hu 2021 [bundle:9] reported positive BMI change, while Kim 2024 [bundle:10], Agarwal 2026 [bundle:16], Mohan 2026 [bundle:5], Sahay 2026 [bundle:4], and Han 2020 [bundle:7] returned null BMI findings — a cluster of severity-4 partial conflicts [exact source: https://doi.org/10.1111/dom.70778]. On body weight, Kumari 2026 [bundle:15] reported negative direction whereas Malin 2026a [bundle:6], Guo 2026 [bundle:1], and Guo 2021 [bundle:14] reported null — a separate severity-4 partial conflict [exact source: https://doi.org/10.1001/jamanetworkopen.2026.15622]. On insulin sensitivity, the tension between Agarwal 2026 [bundle:16] (negative direction) and Qin 2025 [bundle:3] (null) marks a severity-4 partial conflict [exact source: https://doi.org/10.1097/MD.0000000000041061]. The Malin 2026a [bundle:6] exercise-plus-metformin study reported a source-reported estimate, a source-reported estimate, a source-reported estimate, a source-reported estimate, a source-reported estimate, a source-reported estimate, a source-reported estimate, a source-reported estimate, a source-reported estimate alongside many null comparisons including a source-reported estimate, a source-reported estimate, a source-reported estimate, a source-reported estimate, a source-reported estimate, and a source-reported estimate [exact source: https://doi.org/10.1111/dom.70478].

The cardiometabolic profile therefore appears anchored to add-on pharmacology and baseline HbA1c stratum rather than to a uniform metformin effect, consistent with the integrating sentence that mechanistic plausibility coexists with mixed or sparse human-RCT evidence.

### Contextual Adjacent Evidence Outcomes

The contextual other outcome class aggregates human evidence that lies outside the primary cardiometabolic, immune, and frailty endpoints and is dominated by indirect or null findings. Together, these two RCTs anchor the directly-testable mechanistic/biomarker evidence in the corpus.

Indirect observational cohort evidence contributes the remaining contextual other signals and is mixed in direction.

Mechanistically, the contextual other evidence spans three human substrate classes. The Mueller 2021 [bundle:8] RCT is a clinical RCT directly testing a microbiome–SCFA axis in adults (Mueller 2021 [bundle:8]), whereas Marcelo-Calvo 2026 [bundle:12] is a clinical RCT directly interrogating epigenetic-age biology in older people with HIV (Marcelo-Calvo 2026 [bundle:12]) [exact source: https://doi.org/10.2337/dc20-2257]. The human mechanistic substrate underlying these contextual findings thus bridges classic metabolic-axis biomarkers (microbiome, epigenetics) with repurposed-use readouts in dermatology, immunology, neurology, and oncology.

### Immune and Inflammation Outcomes

Two human randomised controlled trials anchor the immune-outcome evidence for metformin intervention in this corpus. Effects of Metformin on Biomarkers 2026 [bundle:31] (RCT, direct) evaluated metformin versus placebo over 4 months in frail/sarcopenic older adults in the MET-PREVENT trial (Effects of Metformin on Biomarkers 2026 [bundle:31]) [exact source: https://doi.org/10.1093/ageing/afaf368.097]. Both studies positioned metformin as an active comparator or intervention with mechanistic/ biomarker endpoints, allowing direct within-corpus comparison.

The detailed per-endpoint decomposition is rendered in the evidence synthesis; the present paragraph need not restate each tuple. By contrast, Effects of Metformin on Biomarkers 2026 [bundle:31] reports a single cited p-value of a source-reported estimate in frail/sarcopenic participants, with effect direction negative for inflammation (Effects of Metformin on Biomarkers 2026 [bundle:31]) [exact source: https://doi.org/10.1093/ageing/afaf368.097]. The source also notes a between-arm insulin change of -178 pg/ml [IQR -462, …] versus placebo at 4 months, providing a mechanistic handle on the inflammatory signal (Effects of Metformin on Biomarkers 2026 [bundle:31]) [exact source: https://doi.org/10.1093/ageing/afaf368.097].

Mechanistically, both clinical RCTs converge on metformin engaging pathways relevant to chronic low-grade inflammation: oxidative-stress modulation and incretin/intestinal-peptide signaling in Schiapaccassa 2019 [bundle:33], and insulin-driven immunometabolic shifts in Effects of Metformin on Biomarkers 2026 [bundle:31] [exact source: https://doi.org/10.1093/ageing/afaf368.097]. The mechanistic substrate underlying this functional finding is consistent with metformin reducing insulin-mediated inflammatory tone in sarcopenic/frail older adults (Effects of Metformin on Biomarkers 2026 [bundle:31]), while in younger drug-naïve women with diabetes and obesity the same drug class produced mixed inflammatory readouts that were study-endpoint dependent (Schiapaccassa 2019 [bundle:33]) [exact source: https://doi.org/10.1093/ageing/afaf368.097]. Across the corpus, the human RCT evidence in the corpus frames metformin as having measurable, but not uniformly directional, anti-inflammatory activity at the doses and durations tested.

The cross-study disagreement map flags an agreement (severity 2) between Effects of Metformin on Biomarkers 2026 [bundle:31] and Schiapaccassa 2019 [bundle:33] on the direction of metformin-related inflammation effects (cross-study disagreement map) [exact source: https://doi.org/10.1093/ageing/afaf368.097]. That flag deserves careful interpretation: Schiapaccassa 2019 [bundle:33] individually reported negative (favourable) inflammation/oxidative-stress changes at multiple endpoints, while Effects of Metformin on Biomarkers 2026 [bundle:31] explicitly recorded a negative effect direction with a source-reported estimate in frail/sarcopenic participants (Effects of Metformin on Biomarkers 2026 [bundle:31]) [exact source: https://doi.org/10.1093/ageing/afaf368.097]. Population differences (drug-naïve women with diabetes/obesity versus frail older adults with sarcopenia) are a more parsimonious explanation for endpoint-level heterogeneity than a true directional disagreement between the two trials.

### Longevity Outcomes

Two observational cohorts in the curated corpus examine longevity-related endpoints under metformin exposure in adult populations. Orchard 2021 [bundle:30] followed older adults and evaluated cancer incidence and mortality in relation to metformin and aspirin use, with Framingham-anchored analytic design typical of community cohorts (Orchard 2021 [bundle:30]) [exact source: https://doi.org/10.1093/geroni/igab046.2339]. Both studies are observational and therefore provide indirect, hypothesis-generating evidence rather than confirmatory randomized data; they are framed here as longevity/cancer-mortality proxies rather than as direct aging-longevity trials.

By contrast, the full-cohort analysis in Maio 2026 [bundle:19] found that metformin exposure was not associated with mortality during the first three years after glioblastoma diagnosis, with the direction of the late-period estimate described as unclear in the available extract (Maio 2026 [bundle:19]) [exact source: https://doi.org/10.1093/noajnl/vdag041]. The two cohorts therefore partition the longevity class into a strong-but-subgroup-conditional mixed signal (Orchard 2021 [bundle:30]) and a null-to-unclear overall signal in advanced neuro-oncology (Maio 2026 [bundle:19]); no p-values were provided in the excerpts for either analysis [exact source: https://doi.org/10.1093/noajnl/vdag041].

Mechanistically, both cohorts sit on a clinical observational platform, so the substrate underlying the reported effect sizes is real-world prescribing rather than the controlled pharmacodynamic exposure of a clinical RCT. The mechanistic substrate for the glioblastoma cohort in Maio 2026 [bundle:19] is even more heterogeneous: post-diagnosis metformin exposure may be confounded by indication, since insulin-resistant patients are more likely to receive it, and the underlying biology of metformin in a high-grade brain tumor is plausibly distinct from its cardiometabolic fingerprint [exact source: https://doi.org/10.1093/noajnl/vdag041]. Preclinical data are not represented in this outcome class within the corpus, so the mechanistic bridge rests on indirect inference from the same observational platforms.

A within-corpus tension is evident between the two cohorts that share the longevity outcome class. These findings are not strictly contradictory — Orchard 2021 [bundle:30]'s signal is subgroup-conditional and oncology-adjacent, while Maio 2026 [bundle:19]'s null is in a high-mortality tumor setting — but they illustrate that the longevity case for metformin is highly context-dependent [exact source: https://doi.org/10.1093/noajnl/vdag041]. The current corpus does not adjudicate between them: no head-to-head randomized comparison is present, and the indirectness labels on both sources preclude treating either as definitive.

### Safety and Comorbidity Outcomes

The clinical RCT enrolled adults with chronic knee osteoarthritis and randomized participants to metformin phonophoresis combined with exercise therapy versus exercise therapy alone, with pain, range of motion, and physical function as the protocol-specified endpoints (Abed 2024 [bundle:18]) [exact source: https://doi.org/10.1186/s13018-024-05120-0]. The trial provides mechanistic/biomarker data on a non-metabolic population and is therefore treated as a safety comorbidity outcome class. Baseline patient characteristics — including age and gender distribution — did not differ significantly between arms, supporting the between-group comparisons that follow. The source does not specify total follow-up duration in months, so this is reported qualitatively as a short-course physiotherapy intervention.

The strongest signals are the a source-reported estimate values (appearing twice in the panel) and the a source-reported estimate and a source-reported estimate comparisons, while several other endpoints cluster around the null. The mixed pattern indicates that not all safety/comorbidity-relevant endpoints respond uniformly to the metformin phonophoresis plus exercise combination within this single trial. Effect-direction coding in the source is recorded as "unclear," which is consistent with the bifurcated p-value distribution shown above.

Mechanistically, metformin phonophoresis is hypothesized to deliver drug to peri-articular soft tissue, plausibly engaging AMPK-related and modest anti-inflammatory pathways that have been associated with symptomatic benefit in knee osteoarthritis in preclinical and translational work (Abed 2024 [bundle:18]) [exact source: https://doi.org/10.1186/s13018-024-05120-0]. The clinical RCT layering onto exercise therapy is consistent with a combinatorial design in which metformin is positioned as an adjunct to a known effective modality rather than as monotherapy. The p-value pattern is compatible with this mechanistic framing: endpoints plausibly downstream of local drug action show tightly distributed small p-values, whereas endpoints with weaker mechanistic coupling to metformin show null-range p-values. The human RCT therefore neither confirms nor refutes a class-level metformin mechanism but does localize several positive findings to specific endpoints.

Within-corpus tension on safety/comorbidity is muted because the supplied evidence base for Metformin contains only a single curated RCT in this outcome class (Abed 2024 [bundle:18]), and the cross-study disagreement map lists no same-outcome non-orthogonal pairs to triangulate against it [exact source: https://doi.org/10.1186/s13018-024-05120-0]. The lack of an opposing signal here should not be read as consensus; rather, it reflects the narrowness of the available safety/comorbidity evidence for this intervention question. Future syntheses would benefit from additional RCTs reporting the same panel of pain, range-of-motion, and physical-function endpoints with harmonized p-value reporting, against which the bifurcated pattern in Abed 2024 [bundle:18] could be tested [exact source: https://doi.org/10.1186/s13018-024-05120-0].

### Frailty Outcomes

Within-corpus tensions in this outcome class are best framed as direct-versus-indirect evidence layering rather than as contradictions. Tavabi 2021 [bundle:26] is a randomized placebo-controlled trial designed to determine whether metformin prevents incident frailty in non-frail participants, with the source excerpts recording the preventive intent and the eligibility definition (Tavabi 2021 [bundle:26]) [exact source: https://doi.org/10.1093/geroni/igab046.2991]. Together these two sources supply one prospective RCT design and one observational extension, with the RCT supplying the only direct frailty endpoint in the corpus.

The source payloads do not carry extractable p-values, effect sizes, or sample-size numerics for the frailty outcome class (Tavabi 2021 [bundle:26]; Espinoza 2022 [bundle:27]) [exact source: https://doi.org/10.1093/geroni/igab046.2991]. Per the source excerpts, Tavabi 2021 [bundle:26] is reported at the design/eligibility layer only — population criterion, preventive intent, and the randomized placebo-controlled architecture — without a tabulated primary-endpoint statistic in the source payload (Tavabi 2021 [bundle:26]) [exact source: https://doi.org/10.1093/geroni/igab046.2991]. Espinoza 2022 [bundle:27] likewise surfaces design tokens (max dose, follow-up duration, safety-listing reference) rather than a frailty effect estimate (Espinoza 2022 [bundle:27]) [exact source: https://doi.org/10.1093/geroni/igac059.2117]. Consequently the quantitative paragraph for this subsection is intentionally light; the evidence synthesis (Per-Study Endpoint Evidence) carries every study × endpoint tuple, and the prose here deliberately references rather than restates any unverified numeric.

Mechanistically, the frailty hypothesis indexed by Tavabi 2021 [bundle:26] sits at the intersection of glucose handling, body-composition trajectories, and the deficit-accumulation framing of frailty that underwrites the outcome instrument family used in the field (Tavabi 2021 [bundle:26]) [exact source: https://doi.org/10.1093/geroni/igab046.2991]. Preclinical data elsewhere in the broader metformin literature — outside this two-source corpus — point to AMPK-related and mitochondrial-quality-control pathways, and the RCT design choice (pre-diabetes enrichment, placebo control, frailty incidence as the endpoint) is consistent with testing whether metabolic-substrate improvement translates into a downstream functional signal in an at-risk older population (Tavabi 2021 [bundle:26]) [exact source: https://doi.org/10.1093/geroni/igab046.2991]. The mechanistic substrate is therefore plausible, but the source corpus for this outcome class does not itself contain the human mechanistic substudies that would close the chain from molecular pathway to functional endpoint.

Within-corpus tensions on the frailty outcome class are framed by directness rather than by effect-size disagreement, because the two sources do not report conflicting numerical results (Tavabi 2021 [bundle:26]; Espinoza 2022 [bundle:27]) [exact source: https://doi.org/10.1093/geroni/igab046.2991]. In practical terms this means the RCT supplies the actionable frailty-prevention signal (if any survives full publication) while the observational extension supplies design and feasibility context that should not be pooled into the same effect estimate as the RCT endpoint. No additional cross-source disagreement is supported by the source payload.

Frailty remains a separate Results slice for Metformin Intervention Metformin Treatment Effects (n=2; claims=28; no extracted directional signal in 2/2 sources; 1 direct; 1 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Tavabi 2021 [bundle:26] (A Randomized Placebo-Controlled Trial of Metformin for Frailty Prevention in Older Adults; 15 extracted claim(s); source-level direction is the coded finding; outcome=Frailty; direction=null; directness=direct; tier=A1) [exact source: https://doi.org/10.1093/geroni/igab046.2991].
- Espinoza 2022 [bundle:27] (CLINICAL TRIAL OF METFORMIN FOR FRAILTY PREVENTION IN COMMUNITY-DWELLING OLDER ADULTS WITH PRE-DIABETES; 13 extracted claim(s); source-level direction is the coded finding; outcome=Frailty; direction=null; directness=indirect; tier=B2) [exact source: https://doi.org/10.1093/geroni/igac059.2117].

## Cross-Domain Synthesis

A first cross-domain tension sits between the direct immune-biomarker RCT of metformin in frail older adults (Effects of Metformin on Biomarkers 2026 [bundle:31]) and the indirect observational evidence on cardiometabolic or longevity endpoints (e.g. Shadyab 2025 [bundle:20], Orchard 2021 [bundle:30], Maio 2026 [bundle:19]) [exact source: https://doi.org/10.1093/ageing/afaf368.097]. The likely boundary condition is that biomarker movement and hard-outcome movement in non-diabetic, older, or oncology populations occupy different evidentiary planes: a small mechanistic shift in a surrogate does not propagate to a mortality-rate shift without additional disease-modifying context, and several methodological cautions exist for treating surrogate endpoints as substitutes for clinical events. What would resolve the apparent disagreement is a single randomized trial whose primary endpoint is incident disability or mortality rather than a biochemical intermediate, with pre-specification of the population in whom a surrogate move is biologically credible.

Another tension runs between direct cardiometabolic RCTs of metformin-containing regimens and indirect cardiometabolic evidence, particularly when the indirect evidence is observational rather than randomized. The direct RCTs (Park 2024 [bundle:2], Qin 2025 [bundle:3], Mohan 2026 [bundle:5], Hu 2021 [bundle:9], Agarwal 2026 [bundle:16]) report a constellation of HbA1c, body-mass-index, and insulin-sensitivity effects with p-values spanning the conventional significance range e.g. The mechanistic boundary condition is plausibly that metformin behaves as a glucose-lowering agent whose acute pharmacodynamic effect on glycemic endpoints is real, but whose longer-horizon effect on body composition, blood pressure, and event rates depends on background therapy, population baseline risk, and the comparator chosen (note Malin 2026a [bundle:6]'s positive body-weight signal and Malin 2026b [bundle:11]'s null body-weight signal, both in the same exercise-training trial context) [exact source: https://doi.org/10.4093/dmj.2023.0259]. Resolution would require head-to-head randomized comparisons stratified by baseline glycemic status, with pre-registered surrogates and hard outcomes in the same cohort.

Another tension pairs the direct mechanistic/biomarker RCTs in non-classical domains (Schiapaccassa 2019 [bundle:33], Mueller 2021 [bundle:8], Marcelo-Calvo 2026 [bundle:12], Effects of Metformin on Biomarkers 2026 [bundle:31]) against the direct clinical/functional RCTs in aging-relevant syndromes (Tavabi 2021 [bundle:26], Espinoza 2022 [bundle:27], Espinoza 2025a [bundle:28], Espinoza 2025b [bundle:29], Abed 2024 [bundle:18]) [exact source: https://doi.org/10.2337/dc20-2257]. A resolution would require trials that pre-specify functional endpoints — including EWGSOP2 grip-strength thresholds — and that are adequately powered to detect within-trial surrogate–functional correlations.

Another tension concerns the conflict between positive and null clinical RCT signals on shared endpoints within the cardiometabolic class — a partial-conflict pattern explicitly flagged in the cross-study disagreement map. Kumari 2026 [bundle:15] reports a negative body-mass-index effect of ranolazine add-on versus metformin monotherapy, while Guo 2026 [bundle:1] and Guo 2021 [bundle:14] are directionally null on the same endpoint [exact source: https://doi.org/10.1001/jamanetworkopen.2026.15622]. The boundary condition is plausibly comparator-dependent: when metformin is the active comparator rather than the intervention, weight effects attenuate, and when it is the add-on rather than the background, additive signals appear (Hu 2021 [bundle:9] reports a coach-directed arm that materially changes the inference) [exact source: https://doi.org/10.3390/nu13082673]. Resolution would be a three-arm randomized comparison (behavioral, metformin, combined) with the same body-mass-index endpoint, an explicit non-inferiority margin, and stratification by baseline BMI category.

Another tension — and arguably the signature one for the metformin-repurposing literature — is between mechanistic plausibility extrapolated from preclinical models and the matched human RCT endpoints in frail, older, or non-diabetic populations. Preclinical lifespan-extension effects of the magnitude classically associated with metformin in animal models coexist with a series of direct human RCTs in older adults that report mixed or null effects on frailty-relevant endpoints (Tavabi 2021 [bundle:26], Espinoza 2022 [bundle:27], Espinoza 2025a [bundle:28], Espinoza 2025b [bundle:29], Effects of Metformin on Biomarkers 2026 [bundle:31]) [exact source: https://doi.org/10.1093/geroni/igab046.2991]. The mechanistic–clinical bridge here is the assumption, drawn from preclinical work, that a mitochondrial or AMPK-related signal can be re-purposed into a human aging-relevant endpoint. The general methodological caution that surrogate associations do not guarantee hard-outcome validity applies, and the candidate boundary conditions — baseline glucose tolerance, age stratum, drug–exercise interaction — are partially visible in Malin 2026a [bundle:6] (positive body-weight/insulin effect) and Malin 2026b [bundle:11] (null blood-pressure/aortic waveform effect) [exact source: https://doi.org/10.1111/dom.70478]. Resolution would require a trial in pre-frail older adults that is sized for a hard functional endpoint, runs long enough to capture events, and incorporates both a metformin monotherapy arm and a metformin-plus-exercise arm so that the preclinical-to-clinical translation can be tested rather than assumed.

### Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as
part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings
explain plausible pathways; indirect findings identify where transfer
across populations, time horizons, or measurement systems remains
uncertain. This separation is important because evidence can be valid
within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical
findings when making patient-facing claims, uses mechanistic evidence
to explain why effects might diverge, and treats discordance as a
signal about applicability rather than as a reason to average unlike
endpoints together.

Cross-domain interpretation compares outcome classes and identifies where signals converge or diverge. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation
separates direct clinical findings from mechanistic and adjacent evidence,
preserving uncertainty where endpoint, population, comparator, or follow-up
differs. This conservative boundary keeps the scientific question visible
without inserting unsupported numeric detail or stronger causal language than
the retained evidence allows. Where studies point in different directions,
the synthesis treats that disagreement as information about design and
applicability rather than as noise. The key question becomes which population,
intervention schedule, comparator, and endpoint layer would be required for the
claim to survive a prospective test. This preserves the practical implication
for readers: favorable signals can justify targeted follow-up, while unresolved
tradeoffs still limit broad clinical or public-health recommendations.

## Endpoint-Sensitivity Framework

We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Discussion

**Thesis:** Across 33 curated reference papers, the evidence base for Metformin shows a context-dependent profile. Positive signals appear in: cardiometabolic. Negative signals appear in: cardiometabolic, immune. Null findings dominate: contextual other, frailty. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Metformin broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile (evidence anchor: Park 2024 [bundle:2]) [exact source: https://doi.org/10.4093/dmj.2023.0259].

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 33 included sources. The evidence-tier distribution is: B2 (n=18), A1 (n=15). By directness, the breakdown is: indirect (n=18), direct (n=15). 25 of 33 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: frail / sarcopenic adults; older adults; type 2 diabetes patients; adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The principal limitation is evidence-role imbalance. The retained corpus contains 15 direct clinical sources, 18 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, which means causal interpretation depends on how much weight is assigned to each evidence tier.

A second limitation is endpoint heterogeneity. Study-level signals span the cardiometabolic outcome class, the contextual adjacent evidence, frailty and cardiometabolic outcome classes, the cardiometabolic, immune and inflammation outcome classes, and the immune and inflammation, cardiometabolic outcome classes; these domains cannot be pooled narratively without losing clinically relevant differences in measurement, population, and study design (evidence anchor: Park 2024 [bundle:2]) [exact source: https://doi.org/10.4093/dmj.2023.0259].

A third limitation is that unsafe source-level numerics are excluded from public prose unless they can be tied to the correct source role and citation context. This protects the manuscript from over-specific drift but can make some sections more conservative than a free-form narrative review.

This framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two.

The final interpretation is therefore intentionally resistant to overstatement. It can support publication-grade synthesis when the evidence profile is transparent, but it does not convert plausible translation into certainty without matching direct evidence.

Readers can weigh each section against the provenance trail published with the run. Every quantitative statement links back to an extraction receipt, and every receipt names its source document, so disagreement between summary and source is detectable rather than silent.

## Conclusion

Substantive conclusion for Metformin Intervention Metformin Treatment Effects: the retained source set shows 33 sources across Cardiometabolic admitted n=19, Contextual Adjacent Evidence admitted n=7, Frailty admitted n=2, Immune and Inflammation admitted n=2; receipt-level directions mixed=2, negative=4, null=5, positive=3, unclear=19; leading source labels Han 2020 [bundle:7], Abed 2024 [bundle:18], Comparison of Efficacy and Safety 2022 [bundle:32] [exact source: https://doi.org/10.3390/jcm9010259]. The paper does not establish standalone clinical actionability.

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates (evidence anchor: Park 2024 [bundle:2]) [exact source: https://doi.org/10.4093/dmj.2023.0259].

### Bounded conclusion

This synthesis supports a bounded interpretation across 33 included sources. The evidence tiers are B2 (n=18), A1 (n=15), and directness is indirect (n=18), direct (n=15). Effect directions are unclear (n=19), null (n=5), negative (n=4), positive (n=3), mixed (n=2), with 25 sources carrying source-traced p-values and 284 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation (evidence anchor: Park 2024 [bundle:2]) [exact source: https://doi.org/10.4093/dmj.2023.0259].

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel (evidence anchor: Park 2024 [bundle:2]) [exact source: https://doi.org/10.4093/dmj.2023.0259].

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits (evidence anchor: Park 2024 [bundle:2]) [exact source: https://doi.org/10.4093/dmj.2023.0259].

## What This Synthesis Adds

This synthesis maps 33 included sources on Metformin Treatment Effects across 6 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the null vs positive between Kim 2024 [bundle:10] and Hu 2021 [bundle:9] on cardiometabolic (severity 4/5), which defines the boundary condition future studies must test rather than smooth over [exact source: https://doi.org/10.3390/nu13082673].

This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 0 | 2 | unclear | direct interventional hard-endpoint gap |
| cardiometabolic | 9 | 10 | mixed, negative, null, positive, unclear | conflict-resolution gap |
| frailty | 1 | 1 | null | replication gap |
| immune and inflammation | 2 | 0 | mixed, negative | replication gap |
| contextual adjacent evidence | 2 | 5 | null, unclear | replication gap |
| safety and comorbidity | 1 | 0 | unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: unclear |
| P2 | cardiometabolic: conflict-resolution gap | 9 direct and 10 indirect sources; direction profile: mixed, negative, null, positive, unclear |
| P3 | frailty: replication gap | 1 direct and 1 indirect sources; direction profile: null |
| P4 | immune and inflammation: replication gap | 2 direct and 0 indirect sources; direction profile: mixed, negative |
| P5 | contextual adjacent evidence: replication gap | 2 direct and 5 indirect sources; direction profile: null, unclear |

### Next-Study Design Recommendation

The next high-yield study for Metformin Treatment Effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Schiapaccassa 2019 [bundle:33]; tier=A1; directness=direct; endpoint=immune; direction=mixed [exact source: https://doi.org/10.1186/s13098-019-0466-2].
- Park 2024 [bundle:2]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear [exact source: https://doi.org/10.4093/dmj.2023.0259].
- Qin 2025 [bundle:3]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear [exact source: https://doi.org/10.1097/MD.0000000000041061].
- Sahay 2026 [bundle:4]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear [exact source: https://doi.org/10.1111/dom.70778].
- Mohan 2026 [bundle:5]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=negative [exact source: https://doi.org/10.1111/1753-0407.70217].
- Han 2020 [bundle:7]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive; representative statistic=P = 0.002 [exact source: https://doi.org/10.3390/jcm9010259].
- Mueller 2021 [bundle:8]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear [exact source: https://doi.org/10.2337/dc20-2257].
- Hu 2021 [bundle:9]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=positive [exact source: https://doi.org/10.3390/nu13082673].
- Kim 2024 [bundle:10]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear [exact source: https://doi.org/10.1155/2024/8915591].
- Marcelo-Calvo 2026 [bundle:12]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear [exact source: https://doi.org/10.1016/j.eclinm.2026.103874].

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Schiapaccassa 2019 [bundle:33]: outcome=immune; directness=direct; tier=A1; direction=mixed; claims=229.
- Park 2024 [bundle:2]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=161.
- Qin 2025 [bundle:3]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=149.
- Sahay 2026 [bundle:4]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=144.
- Mohan 2026 [bundle:5]: outcome=cardiometabolic; directness=direct; tier=A1; direction=negative; claims=132.
- Han 2020 [bundle:7]: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=108.
- Mueller 2021 [bundle:8]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=107.
- Hu 2021 [bundle:9]: outcome=cardiometabolic; directness=direct; tier=A1; direction=positive; claims=73.
- Kim 2024 [bundle:10]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=70.
- Marcelo-Calvo 2026 [bundle:12]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=65.
- Agarwal 2026 [bundle:16]: outcome=cardiometabolic; directness=direct; tier=A1; direction=negative; claims=51.
- Abed 2024 [bundle:18]: outcome=safety comorbidity; directness=direct; tier=A1; direction=unclear; claims=46.
- Tavabi 2021 [bundle:26]: outcome=frailty; directness=direct; tier=A1; direction=null; claims=15.
- Effects of Metformin on Biomarkers 2026 [bundle:31]: outcome=immune; directness=direct; tier=A1; direction=negative; claims=2.
- Comparison of Efficacy and Safety 2022 [bundle:32]: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=1.
- Guo 2026 [bundle:1]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=170.
- Malin 2026a [bundle:6]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=124.
- Malin 2026b [bundle:11]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=69.
- Iraji 2026 [bundle:13]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=65.
- Guo 2021 [bundle:14]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=57.
- Kumari 2026 [bundle:15]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=negative; claims=53.
- Li 2025 [bundle:17]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=49.
- Maio 2026 [bundle:19]: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=41.
- Shadyab 2025 [bundle:20]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=34.
- Behbudi 2025 [bundle:21]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=33.
- Inzucchi 2020 [bundle:22]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=29.
- Shen 2026 [bundle:23]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=26.
- R 2026 [bundle:24]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=20.
- Bilusic 2026 [bundle:25]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=17.
- Espinoza 2022 [bundle:27]: outcome=frailty; directness=indirect; tier=B2; direction=null; claims=13.
- Espinoza 2025a [bundle:28]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=11.
- Espinoza 2025b [bundle:29]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=11.
- Orchard 2021 [bundle:30]: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=8.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 4 null vs negative: Qin 2025 [bundle:3] vs Agarwal 2026 [bundle:16]; Agarwal 2026 [bundle:16] (negative on insulin sensitivity) vs Qin 2025 [bundle:3] (null on insulin sensitivity) — partial conflict [exact source: https://doi.org/10.1097/MD.0000000000041061]
- Severity 4 null vs negative: Kumari 2026 [bundle:15] vs Malin 2026a [bundle:6]; Kumari 2026 [bundle:15] (negative on body mass index) vs Malin 2026a [bundle:6] (null on body mass index) — partial conflict [exact source: https://doi.org/10.1111/dom.70478]
- Severity 4 null vs negative: Kumari 2026 [bundle:15] vs Guo 2026 [bundle:1]; Kumari 2026 [bundle:15] (negative on body mass index) vs Guo 2026 [bundle:1] (null on body mass index) — partial conflict [exact source: https://doi.org/10.1001/jamanetworkopen.2026.15622]
- Severity 4 null vs negative: Kumari 2026 [bundle:15] vs Guo 2021 [bundle:14]; Kumari 2026 [bundle:15] (negative on body mass index) vs Guo 2021 [bundle:14] (null on body mass index) — partial conflict [exact source: https://doi.org/10.3389/fendo.2021.712200]
- Severity 4 null vs negative: Mohan 2026 [bundle:5] vs Sahay 2026 [bundle:4]; Mohan 2026 [bundle:5] (negative on hba1c) vs Sahay 2026 [bundle:4] (null on hba1c) — partial conflict [exact source: https://doi.org/10.1111/dom.70778]
- Severity 4 null vs negative: Mohan 2026 [bundle:5] vs Han 2020 [bundle:7]; Mohan 2026 [bundle:5] (negative on hba1c) vs Han 2020 [bundle:7] (null on hba1c) — partial conflict [exact source: https://doi.org/10.1111/1753-0407.70217]
- Severity 4 null vs positive: Kim 2024 [bundle:10] vs Hu 2021 [bundle:9]; Hu 2021 [bundle:9] (positive on body mass index) vs Kim 2024 [bundle:10] (null on body mass index) — partial conflict [exact source: https://doi.org/10.3390/nu13082673]
- Severity 4 null vs positive: Malin 2026b [bundle:11] vs Malin 2026a [bundle:6]; Malin 2026a [bundle:6] (positive on body weight) vs Malin 2026b [bundle:11] (null on body weight) — partial conflict [exact source: https://doi.org/10.1111/dom.70478]

## References

- **Schiapaccassa 2019 [bundle:33].** _30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal peptides on drug-naïve women with diabetes and obesity: a randomized head-to-head metformin-controlled study._ Diabetology & Metabolic Syndrome, 2019. DOI: 10.1186/s13098-019-0466-2 PMID: 31462933.
- **Guo 2026 [bundle:1].** _HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin._ JAMA Network Open, 2026. DOI: 10.1001/jamanetworkopen.2026.15622 PMID: 42234428.
- **Park 2024 [bundle:2].** _Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial._ Diabetes & Metabolism Journal, 2024. DOI: 10.4093/dmj.2023.0259 PMID: 38650099.
- **Qin 2025 [bundle:3].** _Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with type 2 diabetes: A single-center, prospective, randomized, controlled, noninferiority study with genetic polymorphism analysis._ Medicine, 2025. DOI: 10.1097/MD.0000000000041061 PMID: 39792745.
- **Sahay 2026 [bundle:4].** _Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70778 PMID: 42070788.
- **Mohan 2026 [bundle:5].** _Efficacy and Safety of Glimepiride, Voglibose, and Metformin ER in Type 2 Diabetes: A Randomized, Active‐Controlled Study._ Journal of Diabetes, 2026. DOI: 10.1111/1753-0407.70217 PMID: 41979234.
- **Malin 2026a [bundle:6].** _Metformin attenuates metabolic insulin sensitivity and insulin‐stimulated carbohydrate oxidation after high‐intensity exercise training in adults at risk for metabolic syndrome._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70478 PMID: 41532329.
- **Han 2020 [bundle:7].** _Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial._ Journal of Clinical Medicine, 2020. DOI: 10.3390/jcm9010259 PMID: 31963648.
- **Mueller 2021 [bundle:8].** _Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial._ Diabetes Care, 2021. DOI: 10.2337/dc20-2257 PMID: 34006565.
- **Hu 2021 [bundle:9].** _Effects of a Behavioral Weight Loss Intervention and Metformin Treatment on Serum Urate: Results from a Randomized Clinical Trial._ Nutrients, 2021. DOI: 10.3390/nu13082673 PMID: 34444833.
- **Kim 2024 [bundle:10].** _A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study)._ Journal of Diabetes Research, 2024. DOI: 10.1155/2024/8915591 PMID: 38223523.
- **Malin 2026b [bundle:11].** _Metformin Alters Exercise Training Induced Blood Pressure and Aortic Waveform Adaptations in Adults at Risk for Metabolic Syndrome._ The Journal of Clinical Hypertension, 2026. DOI: 10.1111/jch.70215 PMID: 41796987.
- **Marcelo-Calvo 2026 [bundle:12].** _Metformin and epigenetic age in non-diabetic older people with HIV in Madrid (METFORAGING): a double-blind, randomised, placebo-controlled, pilot trial._ eClinicalMedicine, 2026. DOI: 10.1016/j.eclinm.2026.103874 PMID: 42023167.
- **Iraji 2026 [bundle:13].** _Comparison of the Efficacy of Kligman's Formula Combined With 30% Topical Metformin Versus Kligman's Formula Alone in the Treatment of Melasma._ Journal of Cosmetic Dermatology, 2026. DOI: 10.1111/jocd.70983
- **Guo 2021 [bundle:14].** _Comparison of Clinical Efficacy and Safety of Metformin Sustained-Release Tablet (II) (Dulening) and Metformin Tablet (Glucophage) in Treatment of Type 2 Diabetes Mellitus._ Frontiers in Endocrinology, 2021. DOI: 10.3389/fendo.2021.712200 PMID: 34659110.
- **Kumari 2026 [bundle:15].** _Comparative Study of the Efficacy of Ranolazine as Add-On Therapy With Metformin Versus Metformin Monotherapy on Glycaemic Control in Patients of Type 2 Diabetes Mellitus._ Cureus, 2026. DOI: 10.7759/cureus.101227 PMID: 41669572.
- **Agarwal 2026 [bundle:16].** _Dapagliflozin Plus Metformin Versus Metformin Alone in Overweight and Obese Patients with Polycystic Ovary Syndrome - An Open-Label, Parallel, Randomized Controlled Trial._ Indian Journal of Endocrinology and Metabolism, 2026. DOI: 10.4103/ijem.ijem_635_25 PMID: 41918604.
- **Li 2025 [bundle:17].** _Medication count, including statin or metformin use, is not associated with influenza vaccine responses in older adults._ Vaccine, 2025. DOI: 10.1016/j.vaccine.2025.127913 PMID: 41167013.
- **Abed 2024 [bundle:18].** _Effects of metformin phonophoresis and exercise therapy on pain, range of motion, and physical function in chronic knee osteoarthritis: randomized clinical trial._ Journal of Orthopaedic Surgery and Research, 2024. DOI: 10.1186/s13018-024-05120-0 PMID: 39456024.
- **Maio 2026 [bundle:19].** _Metformin exposure after glioblastoma diagnosis and mortality: A large population-based study._ Neuro-Oncology Advances, 2026. DOI: 10.1093/noajnl/vdag041 PMID: 41788737.
- **Shadyab 2025 [bundle:20].** _Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation._ The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2025. DOI: 10.1093/gerona/glaf095 PMID: 40388602.
- **Behbudi 2025 [bundle:21].** _Effect of Metformin on Clinical Course of Non-Diabetic Patients with Ischemic Stroke._ Galen Medical Journal, 2025. DOI: 10.31661/gmj.v14i.4049 PMID: 42038850.
- **Inzucchi 2020 [bundle:22].** _MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D._ Journal of the Endocrine Society, 2020. DOI: 10.1210/jendso/bvaa046.414
- **Shen 2026 [bundle:23].** _Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug‐Target Mendelian Randomization Study._ Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70598 PMID: 41755790.
- **R 2026 [bundle:24].** _Metformin Repurposing in Neurological Disorders: A Clinical Trial Landscape._ Annals of Neurosciences, 2026. DOI: 10.1177/09727531261421807 PMID: 41930282.
- **Bilusic 2026 [bundle:25].** _The anti-obesogenic metabolite, Lac-Phe, is elevated by metformin treatment in prostate cancer patients._ EMBO Molecular Medicine, 2026. DOI: 10.1038/s44321-026-00408-6 PMID: 41942753.
- **Tavabi 2021 [bundle:26].** _A Randomized Placebo-Controlled Trial of Metformin for Frailty Prevention in Older Adults._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.2991
- **Espinoza 2022 [bundle:27].** _CLINICAL TRIAL OF METFORMIN FOR FRAILTY PREVENTION IN COMMUNITY-DWELLING OLDER ADULTS WITH PRE-DIABETES._ Innovation in Aging, 2022. DOI: 10.1093/geroni/igac059.2117
- **Espinoza 2025a [bundle:28].** _A 2-year Trial of Metformin to Reduce Frailty in Older Adults with Glucose Intolerance._ Innovation in Aging, 2025. DOI: 10.1093/geroni/igaf122.1648
- **Espinoza 2025b [bundle:29].** _METFORMIN TO TARGET FRAILTY IN OLDER ADULTS._ Innovation in Aging, 2025. DOI: 10.1093/geroni/igaf122.1104
- **Orchard 2021 [bundle:30].** _Associations between Metformin and Aspirin Use on Cancer Incidence and Mortality in Older Adults._ Innovation in Aging, 2021. DOI: 10.1093/geroni/igab046.2339
- **Effects of Metformin on Biomarkers 2026 [bundle:31].** _3778 Effects of metformin on biomarkers in older people with sarcopenia: analysis from the MET-PREVENT randomised controlled trial._ Age and Ageing, 2026. DOI: 10.1093/ageing/afaf368.097
- **Comparison of Efficacy and Safety 2022 [bundle:32].** _Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial._ National Journal of Physiology, Pharmacy and Pharmacology, 2022. DOI: 10.5455/njppp.2022.12.062851202217862022

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "c9c5e831-56e1-4de3-add7-3b62d7a5a19f",
  "title": "Research Synthesis: Metformin Treatment Effects \u2014 full paper"
}